Risk Factors and Clinical Outcomes of Bacterial Conjunctivitis in Diabetic and Non-Diabetic Patients
Background: Bacterial conjunctivitis is a common external ocular infection. Diabetes mellitus (DM) impairs host immunity and ocular surface defences, potentially altering clinical presentation, microbial patterns, and outcomes. Aim: To compare risk factors, microbial spectrum, antibiotic susceptibility, and clinical outcomes of bacterial conjunctivitis in diabetic versus non-diabetic patients and to assess the impact of glycaemic control. Methods: A prospective comparative study was conducted at Al-Kindy and Imam Ali General Hospitals, Baghdad (January 2024–June 2025). Two hundred clinically diagnosed cases were enrolled and divided into Group A (DM; n=100) and Group B (non-DM; n=100). History, slit-lamp examination, and conjunctival swabs for culture and Kirby–Bauer susceptibility testing (CLSI standards) were performed. Outcomes included healing time, recurrence within 3 weeks, complications, and hospitalization. Statistical significance was set at p<0.05 (SPSS v26). Results: Staphylococcus aureus was the predominant pathogen in both groups. Diabetics had more mixed infections (28% vs 12%, p=0.01) and longer mean healing time (8.2±1.4 vs 5.6±1.2 days, p<0.001). Recurrence (14% vs 5%, p=0.03), keratitis (9% vs 2%, p=0.04), corneal ulcer (5% vs 0%, p=0.02), and hospitalization (12% vs 3%, p=0.01) were higher in diabetics. Among antibiotics, moxifloxacin (90–94%) and tobramycin (88–90%) showed the highest sensitivities; erythromycin sensitivity was lower in diabetics (46% vs 64%, p=0.03). Poor glycaemic control (HbA1c>8%) independently correlated with delayed healing (9.3±1.5 vs 6.5±1.2 days, p<0.001), higher recurrence (20% vs 6%, p=0.01), increased keratitis (12% vs 3%, p=0.03), and greater resistance (36% vs 18%, p=0.04). Conclusion: DM significantly worsens the clinical course of bacterial conjunctivitis, increasing polymicrobial infection, resistance, complications, and recovery time. Early culture-guided therapy plus strict glycaemic control are essential to optimise outcomes.